Further, in a BRAF-mutated papillary thyroid cancer cell line (BCPAP), vemurafenib, an inhibitor of mutant BRAF activity, was shown to upregulate VCAM-1 expression, which was reduced by the administration of the Akt inhibitor MK2206 [63]. The gene discussed is AKT1; the disease is thyroid gland papillary carcinoma.